Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
Reads0
Chats0
TLDR
A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.Abstract:
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.read more
Citations
More filters
Journal ArticleDOI
Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 Kip1 axis
Hui Liu,Yuan Liu,Zhaolian Bian,Jing Zhang,Rui Zhang,Xiaoyu Chen,Yan-Xia Huang,Yang Wang,Jin-Shui Zhu +8 more
TL;DR: It is demonstrated that circYAP1 functions as a tumor suppressor in GC cells by targeting the miR-367-5p/p27 Kip1 axis and may provide a prognostic indicator of survival in GC patients.
Journal ArticleDOI
MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis
Yan Yang,Lili Ding,Qun Hu,Jia Xia,Junjie Sun,Xu-Dong Wang,Hua Xiong,Deepak Gurbani,Lianbo Li,Yan Liu,Yan Liu,Aiguo Liu +11 more
TL;DR: MiR-218 acts as a tumor suppressor in lung cancer via IL-6/STAT3 signaling pathway regulation and negatively regulated IL- 6 receptor and JAK3 gene expression by directly targeting the 3′-UTR of their mRNAs.
Journal ArticleDOI
Molecular pathogenesis of sporadic colorectal cancers
TL;DR: This review describes the genetic pathways of sporadic CRCs and their clinicopathologic features, and summarizes the present knowledge of this research field and discusses its prospects.
Journal ArticleDOI
LncRNA UCA1 in anti-cancer drug resistance.
TL;DR: The potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors, is highlighted and its potential in future clinical applications is discussed.
Journal ArticleDOI
The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus
Zong-Ming Zhang,Eric C. H. Lai,Chong Zhang,Hongwei Yu,Zhuo Liu,Bo-jiang Wan,Li-Min Liu,Zu-hao Tian,Hai Deng,Qiu-hong Sun,Xiaoping Chen +10 more
TL;DR: For those resectable tumors, the better choice for treatment of HCC with PVTT should be hepatectomy and removal of PVTT, and the multidisciplinary treatments may further improve the quality of life and prolong the survival period for the HCC patients associated with PV TT.
References
More filters
Journal ArticleDOI
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
TL;DR: The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.
Journal ArticleDOI
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
TL;DR: This timely monograph is a distillation of knowledge of hepatitis B, C and D, based on a review of 1000 studies by a small group of scientists, and it is concluded that hepatitis D virus cannot be classified as a human carcinogen.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.